Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ARQT on Nasdaq
Shares outstanding
120,138,422
Price per share
$29.04
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
125,772,833
Total reported value
$2,369,578,876
% of total 13F portfolios
0%
Share change
-1,292,158
Value change
-$12,687,586
Number of holders
234
Price from insider filings
$29.04
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JENNISON ASSOCIATES LLC 10% +6% $230,991,369 +$16,837,739 12,254,119 +7.9% Jennison Associates LLC 30 Sep 2025
PRUDENTIAL FINANCIAL INC 10% $158,869,590 11,954,070 PRUDENTIAL FINANCIAL INC 31 Mar 2025
Frazier Life Sciences VIII, L.P. 7.5% $141,578,961 8,943,712 Patrick J. Heron 18 Aug 2025
Polar Capital Holdings Plc 4.2% -24% $79,252,452 -$26,911,047 5,006,472 -25% Polar Capital Holdings Plc 30 Jun 2025

As of 30 Sep 2025, 234 institutional investors reported holding 125,772,833 shares of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT). This represents 105% of the company’s total 120,138,422 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) together control 88% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JENNISON ASSOCIATES LLC 10% 12,254,119 +10% 0.13% $230,990,144
Rubric Capital Management LP 8.9% 10,749,457 0% 2.7% $202,627,264
SUVRETTA CAPITAL MANAGEMENT, LLC 8.7% 10,478,000 -9.2% 6% $197,510,300
Frazier Life Sciences Management, L.P. 8.2% 9,874,511 0% 5.6% $186,134,532
BlackRock, Inc. 7.1% 8,573,995 +0.48% 0% $161,619,806
VANGUARD GROUP INC 5.9% 7,146,090 +1.4% 0% $134,703,797
Polar Capital Holdings Plc 4.4% 5,298,754 +5.8% 0.48% $99,881,513
STATE STREET CORP 3.9% 4,641,315 +2.5% 0% $87,488,788
GILDER GAGNON HOWE & CO LLC 3.7% 4,429,108 +6.6% 0.85% $83,488,686
MORGAN STANLEY 3.6% 4,276,394 -0.88% 0% $80,610,030
UBS Group AG 2.5% 2,948,438 +0.36% 0.01% $55,578,057
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,606,465 +0.93% 0% $49,139,527
JANUS HENDERSON GROUP PLC 2% 2,398,031 +5.9% 0.02% $45,178,904
FRANKLIN RESOURCES INC 1.9% 2,311,019 -15% 0.01% $43,562,708
Pivotal bioVenture Partners Investment Advisor LLC 1.8% 2,120,508 0% 23% $39,971,576
D. E. Shaw & Co., Inc. 1.8% 2,118,713 -2% 0.03% $39,937,740
Perpetual Ltd 1.7% 2,024,606 +7534% 0.47% $38,163,823
Ensign Peak Advisors, Inc 1.7% 1,993,055 -0.42% 0.06% $37,569,087
GOLDMAN SACHS GROUP INC 1.5% 1,804,988 -4.5% 0% $34,024,024
AMERICAN CENTURY COMPANIES INC 1.4% 1,662,470 -3.6% 0.02% $31,337,590
Nuveen, LLC 1.1% 1,370,356 +79% 0.01% $25,831,211
GW&K Investment Management, LLC 0.98% 1,172,041 -15% 0.2% $22,093,000
Driehaus Capital Management LLC 0.91% 1,097,004 +1% 0.15% $20,678,525
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.83% 999,434 +3.6% 0% $18,839,331
NORTHERN TRUST CORP 0.78% 940,202 +1.2% 0% $17,722,808

Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,390,714 $69,342,504 -$15,202,042 $29.04 22
2025 Q3 125,772,833 $2,369,578,876 -$12,687,586 $18.85 234
2025 Q2 127,080,415 $1,781,069,063 +$21,637,099 $14.02 228
2025 Q1 125,020,171 $1,954,461,834 -$63,284,148 $15.64 238
2024 Q4 128,700,196 $1,792,792,113 +$16,085,473 $13.93 205
2024 Q3 128,466,844 $1,196,656,614 +$14,233,673 $9.30 187
2024 Q2 126,510,125 $1,176,681,365 +$21,044,712 $9.30 185
2024 Q1 109,404,335 $1,084,075,908 +$267,002,535 $9.91 125
2023 Q4 159,312 $515,355 -$27,195 $3.23 3
2023 Q3 67,067,552 $356,213,729 -$29,952,633 $5.31 132
2023 Q2 71,670,340 $683,083,308 -$6,790,555 $9.53 132
2023 Q1 71,586,458 $787,439,086 +$44,291,408 $11.00 139
2022 Q4 65,585,911 $970,655,158 +$88,099,904 $14.80 136
2022 Q3 59,305,828 $1,133,330,532 +$193,854,925 $19.11 135
2022 Q2 49,064,239 $1,045,579,402 +$17,638,645 $21.31 110
2022 Q1 48,181,520 $927,366,760 +$37,239,484 $19.26 103
2021 Q4 45,692,425 $947,657,713 -$2,868,603 $20.74 86
2021 Q3 45,669,050 $1,090,746,157 +$4,204,309 $23.89 100
2021 Q2 45,448,921 $1,240,158,476 -$38,012,543 $27.29 99
2021 Q1 46,828,892 $1,354,646,559 +$171,081,997 $28.93 91
2020 Q4 40,821,727 $1,148,322,120 +$134,359,690 $28.13 77
2020 Q3 34,765,777 $1,018,640,387 +$28,883,436 $29.30 60
2020 Q2 33,776,828 $1,021,408,758 +$33,104,673 $30.24 55
2020 Q1 32,683,150 $973,960,747 +$973,281,288 $29.80 48